Announcements Trials
Browse Landscape

Phase

Phase NA 48Phase 3 17Phase 4 6Phase 1 5Phase EARLY_PHASE1 3Phase 2 3Phase 2/3 2Phase 1/2 2

Status

Completed 4Withdrawn 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Neoplasms 2009Carcinoma, Non-Small-Cell Lung 1222Breast Neoplasms 1214Leukemia, Myeloid, Acute 965Neoplasm Metastasis 900Melanoma 777Colorectal Neoplasms 749Lymphoma 725Multiple Myeloma 723Ovarian Neoplasms 673Pancreatic Neoplasms 664Prostatic Neoplasms 657Lymphoma, Non-Hodgkin 657Recurrence 636Precursor Cell Lymphoblastic Leukemia-Lymphoma 583Lung Neoplasms 559Leukemia, Lymphocytic, Chronic, B-Cell 555Glioblastoma 527Leukemia 485Lymphoma, Large B-Cell, Diffuse 440Lymphoma, Follicular 418Brain Neoplasms 413Squamous Cell Carcinoma of Head and Neck 388Stomach Neoplasms 386Carcinoma, Renal Cell 384Myelodysplastic Syndromes 381Carcinoma, Hepatocellular 367Advanced Solid Tumors 356Lymphoma, Mantle-Cell 345Glioma 342

Interventions

Tablets 1LFA102 monoclonal antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Myofibroma × Clear all
NCT01338831 2020-12-17

Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

Novartis

Phase 1 Completed
73 enrolled
BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms, Myofibroma

NCT03156127 2017-08-10

A Study to Compare the Pharmacokinetics and Safety/Tolerability of BR-UPS (Ulipristal Acetate) 5 mg Tablet With Inisia (Ulipristal Acetate) 5 mg Tablet

Boryung Pharmaceutical Co., Ltd

Phase 1 Withdrawn

Myofibroma

NCT00543790 2010-10-28

Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 1 Completed
48 enrolled

Leiomyoma, Myofibroma

NCT00444704 2009-07-10

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRA-027 Administered to Healthy Japanese Females

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 1 Completed

Leiomyoma, Myofibroma

NCT00427544 2007-12-05

Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 1 Completed

Leiomyoma, Myofibroma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡